NeuroVive’s KL1333 program granted orphan drug designation by the European Commission
Lund, Sweden, 13 December 2017 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), announced today that the European Commission has granted orphan drug designation (ODD) for the company’s KL1333 program for oral treatment of the genetic mitochondrial disease Mitochondrial Myopathy, Encephalopathy, Lactic acidosis and Stroke-like episodes (MELAS).The decision by the Commission confirms the opinion previously issued by the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP), which was communicated by NeuroVive on 8 November 2017. The orphan drug